As the results of a preclinical study suggested that ALL cells were dependent on both BCL-2 and BCL-XL, navitoclax (a BCL-2 and BCL-XL inhibitor) was tested in combination with venetoclax and chemotherapy for pediatric and adult patients with relapsed/refractory ALL or lymphoblastic lymphoma [114]. This evidence concerns the gene BCL2L1 and lymphoblastic lymphoma.